Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 years or older;~* positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay for COVID-19 in a respiratory tract sample;~* intubated and mechanically ventilated;~* acute onset of ARDS, as defined by Berlin criteria as moderate-to-severe ARDS,3 which includes: (i) having pneumonia or worsening respiratory symptoms, (ii) bilateral pulmonary infiltrates on chest imaging (x-ray or CT scan), (iii) absence of left atrial hypertension, pulmonary capillary wedge pressure \<18 mmHg, or no clinical signs of left heart failure, and (iv) hypoxemia, as defined by a PaO2/FiO2 ratio of ≤200 mmHg on positive end-expiratory pressure (PEEP) of ≥5 cmH2O, regardless of FiO2.~Exclusion Criteria:~* Routine treatment with corticosteroids during the previous week irrespective of dose;~* Corticosteroid use within the previous 24 h of more than 20 mg of dexamethasone or equivalent;~* Patients with a known contraindication to corticosteroids;~* Decision by a physician that involvement in the trial is not in the patient's best interest;~* Pregnancy and breast-feeding;~* Participation in another therapeutic trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control group (Type: NO_INTERVENTION): Patients will be treated with standard intensive care
- Dexamethasone (Type: ACTIVE_COMPARATOR): Standard intensive care plus dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).